Streetbeat News

Regulatory

IDYA

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported a strong balance sheet with $511.1M in cash and securities as of September 30, 2023. The company expects the funds, including $134.7M from follow-on financing and $10M receivable from GSK, to support operations into 2028. IDEAYA announced updates at the J.P. Morgan Healthcare Conference, including international patient enrollment in a Phase 2/3 trial for darovasertib and crizotinib, and various clinical program updates for 2024. The company is also advancing collaborations with GSK and targeting IND submissions and new development candidate nominations in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 07, 2024 | 8:15 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) provided updates on its pipeline and business operations before the 42nd Annual J.P. Morgan Healthcare Conference. Key highlights include the launch of CASGEVY in the U.S., UK, and Bahrain, completion of pivotal studies for cystic fibrosis treatments, and progress in studies for sickle cell disease, acute pain, peripheral neuropathic pain, kidney disease, type 1 diabetes, and myotonic dystrophy. Vertex also revised patient estimates for cystic fibrosis and sickle cell disease. The company expects to share study results and advance various programs in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 07, 2024 | 8:06 pm

ASND

Specialised Therapeutics Asia has signed an exclusive agreement with Ascendis Pharma to distribute and commercialize three endocrinology therapies in Australia and select South-East Asia countries. The therapies include SKYTROFA for paediatric growth hormone deficiency, YORVIPA for hypoparathyroidism, and TransCon CNP for achondroplasia. The agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. Two of the products are already internationally approved.

Portfolio Pulse from Charles Gross

January 07, 2024 | 7:34 pm

ALK

SPR

VGK

The European Union Aviation Safety Agency (EASA) has adopted the FAA's emergency airworthiness directive for the Boeing 737-9, stating that no EU operators are affected by this directive.

Portfolio Pulse from Charles Gross

January 07, 2024 | 3:30 pm

BLK

BTCUSD

SHIBUSD

The first week of 2024 saw mixed expectations for a Bitcoin ETF approval by the SEC, with only 39% of financial advisors confident in an approval this year. BlackRock, VanEck, and Valkyrie Investments are awaiting the SEC's decision on their Bitcoin ETF applications. Economist Peter Schiff warned that the market might be disappointed by the outcome. Shiba Inu's burn rate surged by 373%, indicating a cautiously optimistic outlook for 2024. Crypto analysts highlighted the importance of Bitcoin and other cryptocurrencies like Solana and Ethereum, with the upcoming Bitcoin halving event also being a point of focus.

Portfolio Pulse from Benzinga Neuro

January 07, 2024 | 2:07 pm

ALK

SPR

SPY

The FAA has issued a temporary grounding order for certain Boeing 737 Max 9 aircraft operated by U.S. airlines or within U.S. territory. This action may affect the operations of airlines using this aircraft model and could have implications for Boeing's stock as well as its suppliers and the broader market.

Portfolio Pulse from Charles Gross

January 07, 2024 | 3:01 am

ATAI

CMPS

CYBN

DMTTF

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100 million in Series A funding to support FDA approval of MDMA for PTSD treatment. The company will rebrand as Lykos Therapeutics. The investment reflects growing interest in psychedelic treatments for mental illnesses. Atai Life Sciences, Compass Pathways, and Cybin Inc. are also advancing in the psychedelic space with significant investments and acquisitions.

Portfolio Pulse from Maureen Meehan

January 06, 2024 | 8:59 pm

ALK

Boeing is aware of an incident involving Alaska Airlines Flight 1282 and is gathering more information. Boeing's technical team is prepared to support the investigation in coordination with the airline.

Portfolio Pulse from Charles Gross

January 06, 2024 | 3:35 pm

FSR

KARS

RIVN

TSLA

Electric vehicle stocks fell in the week ending Jan. 5, with Tesla's Q4 deliveries exceeding expectations but not enough to lift the sector. Tesla lost its global EV leader status to BYD, faced a recall in China, and will provide 2024 guidance on Jan. 24. Rivian's Q4 deliveries slightly missed estimates, while Fisker adopted a dealer distribution model. Ford adjusted F-150 Lightning prices, and GM plans to compensate buyers for lost EV tax credits. The KraneShares Electric Vehicles ETF fell by 5.53% for the week.

Portfolio Pulse from Shanthi Rexaline

January 06, 2024 | 2:59 pm

BLK

BTCUSD

GBTC

Better Markets CEO Dennis M. Kelleher has warned the SEC that approving a spot Bitcoin ETF would be a 'historic mistake' and could lead to 'massive investor harm.' Bloomberg ETF analyst James Seyffart criticized Kelleher's stance, calling it a 'criminal move.' The SEC is set to decide on the Bitcoin ETF by Jan. 10, with 11 applicants having submitted amendment forms. BlackRock Inc. and Grayscale Investments have met with the SEC to discuss Bitcoin ETFs. BTC's price was slightly up at the time of reporting.

Portfolio Pulse from Rounak Jain

January 06, 2024 | 10:02 am